387 related articles for article (PubMed ID: 11016962)
41. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
Celichowski P; Turi M; Charvátová S; Radhakrishnan D; Feizi N; Chyra Z; Šimíček M; Jelínek T; Bago JR; Hájek R; Hrdinka M
J Transl Med; 2023 Mar; 21(1):197. PubMed ID: 36922828
[TBL] [Abstract][Full Text] [Related]
42. Next-Generation CAR T-cell Therapies.
Young RM; Engel NW; Uslu U; Wellhausen N; June CH
Cancer Discov; 2022 Jul; 12(7):1625-1633. PubMed ID: 35417527
[TBL] [Abstract][Full Text] [Related]
43. Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.
Heipertz EL; Zynda ER; Stav-Noraas TE; Hungler AD; Boucher SE; Kaur N; Vemuri MC
Front Immunol; 2021; 12():732135. PubMed ID: 34925314
[TBL] [Abstract][Full Text] [Related]
44. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
[TBL] [Abstract][Full Text] [Related]
45. Delivery technologies to engineer natural killer cells for cancer immunotherapy.
El-Mayta R; Zhang Z; Hamilton AG; Mitchell MJ
Cancer Gene Ther; 2021 Sep; 28(9):947-959. PubMed ID: 33888870
[TBL] [Abstract][Full Text] [Related]
46. Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology.
Schmidt P; Raftery MJ; Pecher G
Front Immunol; 2020; 11():611163. PubMed ID: 33488617
[TBL] [Abstract][Full Text] [Related]
47. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
48. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
49. A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy.
Pomeroy EJ; Hunzeker JT; Kluesner MG; Lahr WS; Smeester BA; Crosby MR; Lonetree CL; Yamamoto K; Bendzick L; Miller JS; Geller MA; Walcheck B; Felices M; Webber BR; Starr TK; Moriarity BS
Mol Ther; 2020 Jan; 28(1):52-63. PubMed ID: 31704085
[TBL] [Abstract][Full Text] [Related]
50. An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.
Zhu H; Kaufman DS
Methods Mol Biol; 2019; 2048():107-119. PubMed ID: 31396935
[TBL] [Abstract][Full Text] [Related]
51. A safe and potent anti-CD19 CAR T cell therapy.
Ying Z; Huang XF; Xiang X; Liu Y; Kang X; Song Y; Guo X; Liu H; Ding N; Zhang T; Duan P; Lin Y; Zheng W; Wang X; Lin N; Tu M; Xie Y; Zhang C; Liu W; Deng L; Gao S; Ping L; Wang X; Zhou N; Zhang J; Wang Y; Lin S; Mamuti M; Yu X; Fang L; Wang S; Song H; Wang G; Jones L; Zhu J; Chen SY
Nat Med; 2019 Jun; 25(6):947-953. PubMed ID: 31011207
[TBL] [Abstract][Full Text] [Related]
52. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
[TBL] [Abstract][Full Text] [Related]
53. Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation.
Müller E; Speth M; Christopoulos PF; Lunde A; Avdagic A; Øynebråten I; Corthay A
Front Immunol; 2018; 9():2520. PubMed ID: 30450098
[TBL] [Abstract][Full Text] [Related]
54. Macrophage polarity in cancer: A review.
Najafi M; Hashemi Goradel N; Farhood B; Salehi E; Nashtaei MS; Khanlarkhani N; Khezri Z; Majidpoor J; Abouzaripour M; Habibi M; Kashani IR; Mortezaee K
J Cell Biochem; 2019 Mar; 120(3):2756-2765. PubMed ID: 30270458
[TBL] [Abstract][Full Text] [Related]
55. CD38 Is Robustly Induced in Human Macrophages and Monocytes in Inflammatory Conditions.
Amici SA; Young NA; Narvaez-Miranda J; Jablonski KA; Arcos J; Rosas L; Papenfuss TL; Torrelles JB; Jarjour WN; Guerau-de-Arellano M
Front Immunol; 2018; 9():1593. PubMed ID: 30042766
[TBL] [Abstract][Full Text] [Related]
56. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.
Fraietta JA; Nobles CL; Sammons MA; Lundh S; Carty SA; Reich TJ; Cogdill AP; Morrissette JJD; DeNizio JE; Reddy S; Hwang Y; Gohil M; Kulikovskaya I; Nazimuddin F; Gupta M; Chen F; Everett JK; Alexander KA; Lin-Shiao E; Gee MH; Liu X; Young RM; Ambrose D; Wang Y; Xu J; Jordan MS; Marcucci KT; Levine BL; Garcia KC; Zhao Y; Kalos M; Porter DL; Kohli RM; Lacey SF; Berger SL; Bushman FD; June CH; Melenhorst JJ
Nature; 2018 Jun; 558(7709):307-312. PubMed ID: 29849141
[TBL] [Abstract][Full Text] [Related]
57. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
Park JH; Rivière I; Gonen M; Wang X; Sénéchal B; Curran KJ; Sauter C; Wang Y; Santomasso B; Mead E; Roshal M; Maslak P; Davila M; Brentjens RJ; Sadelain M
N Engl J Med; 2018 Feb; 378(5):449-459. PubMed ID: 29385376
[TBL] [Abstract][Full Text] [Related]
58. CAR T Cells Releasing IL-18 Convert to T-Bet
Chmielewski M; Abken H
Cell Rep; 2017 Dec; 21(11):3205-3219. PubMed ID: 29241547
[TBL] [Abstract][Full Text] [Related]
59. Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages.
Müller E; Christopoulos PF; Halder S; Lunde A; Beraki K; Speth M; Øynebråten I; Corthay A
Front Immunol; 2017; 8():1383. PubMed ID: 29123526
[TBL] [Abstract][Full Text] [Related]
60. The BCL-2 arbiters of apoptosis and their growing role as cancer targets.
Adams JM; Cory S
Cell Death Differ; 2018 Jan; 25(1):27-36. PubMed ID: 29099483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]